| scholarly article | Q13442814 |
| P356 | DOI | 10.1172/JCI117001 |
| P8608 | Fatcat ID | release_smk3cuxzhjbmdapsvbiyoc7r64 |
| P932 | PMC publication ID | 293872 |
| P698 | PubMed publication ID | 7906694 |
| P50 | author | Jeffrey A Kern | Q63373813 |
| P2093 | author name string | Schwartz DA | |
| Weiner D | |||
| Rodenhuis S | |||
| Robinson RA | |||
| Slebos RJ | |||
| Lager D | |||
| Top B | |||
| P2860 | cites work | Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. | Q33825340 |
| Oncogenes and tumor suppressor genes in human lung carcinogenesis | Q36404302 | ||
| Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer | Q37581342 | ||
| Functional inactivation of genes by dominant negative mutations | Q38178605 | ||
| A new international staging system for lung cancer | Q39729989 | ||
| Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines | Q41633694 | ||
| Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas | Q41684074 | ||
| p185neu expression in human lung adenocarcinomas predicts shortened survival | Q41725055 | ||
| Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes | Q42804780 | ||
| The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation | Q42804813 | ||
| Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. | Q42814628 | ||
| Evidence by in situ hybridization that c-erbB-2 proto-oncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas | Q43680917 | ||
| DNA alterations at proto-oncogene loci and their clinical significance in operable non-small cell lung cancer | Q44682671 | ||
| Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products | Q44830802 | ||
| A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues | Q45122872 | ||
| Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics. | Q45946068 | ||
| Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines | Q46937946 | ||
| p53: a frequent target for genetic abnormalities in lung cancer. | Q52486321 | ||
| Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer | Q53494420 | ||
| Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. | Q53520000 | ||
| Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma | Q58454772 | ||
| Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung | Q68082107 | ||
| ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent | Q68254101 | ||
| Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer | Q68259992 | ||
| K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung | Q68532141 | ||
| A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides | Q69022841 | ||
| Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer | Q69373028 | ||
| Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung | Q69855061 | ||
| Karyotypic characterization of established cell lines and short-term cultures of human lung cancers | Q70078782 | ||
| Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung | Q70193311 | ||
| Cancer statistics, 1993 | Q70535113 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 516-520 | |
| P577 | publication date | 1994-02-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas | |
| P478 | volume | 93 |
| Q43173320 | Absence of ras gene mutations in early gastric carcinomas |
| Q73488908 | Adjuvant chemotherapy for non-small cell lung cancer |
| Q36072192 | Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis |
| Q34936052 | Clinical impact of novel treatment strategies |
| Q77711290 | Clinical implications of molecular abnormalities in lung cancer |
| Q36641208 | Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer |
| Q42106918 | Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study |
| Q77376768 | Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival |
| Q47771319 | Discrimination of multiple primary lung cancers from intrapulmonary metastasis based on the expression of four cancer-related proteins |
| Q40405623 | EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway |
| Q40973384 | Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line |
| Q38331804 | Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis |
| Q38456543 | Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry |
| Q29614443 | Gene-expression profiles predict survival of patients with lung adenocarcinoma |
| Q34208895 | Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. |
| Q33588251 | Genetics and pulmonary medicine. 7. Somatic mutations in the development of lung cancer |
| Q39729571 | Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. |
| Q38997358 | In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites. |
| Q36420159 | K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer |
| Q90633220 | KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy |
| Q38669282 | KRAS-Mutant Lung Cancers in the Era of Targeted Therapy |
| Q36135626 | Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections |
| Q33972805 | Lung cancer * 9: Molecular biology of lung cancer: clinical implications |
| Q37227208 | MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients |
| Q33891465 | Molecular and genetic aspects of lung cancer |
| Q74569409 | Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications |
| Q34569440 | Molecular biology of lung cancer: clinical implications. |
| Q33793308 | Molecular pathogenesis of lung cancer |
| Q37913090 | Molecular predictors of prognosis in lung cancer |
| Q36642239 | Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer |
| Q44120928 | Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. |
| Q41023437 | New prognostic factors in resectable non-small cell lung cancer |
| Q34679340 | Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results |
| Q41523353 | Non-small cell lung cancer: clinical value of new biological predictors |
| Q36116240 | Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue |
| Q40864750 | Primary adenocarcinoma of the lung--histological subtypes and outcome after surgery, using the IASLC/ATS/ERS classification of lung adenocarcinoma |
| Q34384392 | Prognostic factors in stage I/II non-small cell lung cancer |
| Q73181191 | Prognostic impact of telomerase activity in non-small cell lung cancers |
| Q41519933 | Prognostic markers in resectable non-small cell lung cancer |
| Q34447423 | Prognostic molecular markers in non-small cell lung cancer |
| Q74341106 | Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung |
| Q53431081 | Progress in understanding the molecular pathogenesis of human lung cancer. |
| Q33595441 | Role of bronchoscopy in lung cancer research |
| Q71863856 | Serum Level and Tissue Expression of c-erbB-2 Protein in Lung Adenocarcinoma |
| Q36335248 | Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma |
| Q53759964 | Study of prognostic predictors for non-small cell lung cancer. |
| Q74522923 | The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients |
| Q35216052 | The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature |
| Q24650902 | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
| Q35013566 | The role of new agents in the treatment of non-small cell lung cancer. |
| Q36292265 | The role of transforming growth factor alpha production and ErbB-2 overexpression in induction of tumorigenicity of lung epithelial cells |
| Q36158717 | Therapeutic targeting of receptor tyrosine kinases in lung cancer |
| Q34325219 | Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies |
| Q34133830 | Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe |
| Q80941653 | [Prognostic value of ERBB2 amplification and protein expression in small cell lung cancer] |
| Q78844837 | [Study of epidermal growth factor receptor concentration (EGFR) in lung adenocarcinomas. Association with high erbB2 oncogenic protein levels] |
| Q74291349 | [Usefulness of cytosolic tissue-type plasminogen activator levels in lung adenocarcinomas] |
| Q52122642 | c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. |
Search more.